86 related articles for article (PubMed ID: 31097086)
1. Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
Vad-Nielsen J; Gammelgaard KR; Daugaard TF; Nielsen AL
Lung Cancer; 2019 Jun; 132():132-140. PubMed ID: 31097086
[TBL] [Abstract][Full Text] [Related]
2. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
Gohlke L; Alahdab A; Oberhofer A; Worf K; Holdenrieder S; Michaelis M; Cinatl J; Ritter CA
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834189
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
Haque I; Kawsar HI; Motes H; Sharma M; Banerjee S; Banerjee SK; Godwin AK; Huang CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291316
[TBL] [Abstract][Full Text] [Related]
5. Caffeic acid phenethyl ester surmounts acquired resistance of AZD9291 in non-small cell lung cancer cells.
Twum Y; Marshall K; Gao W
Biofactors; 2023; 49(6):1143-1157. PubMed ID: 37555475
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
Song KA; Niederst MJ; Lochmann TL; Hata AN; Kitai H; Ham J; Floros KV; Hicks MA; Hu H; Mulvey HE; Drier Y; Heisey DAR; Hughes MT; Patel NU; Lockerman EL; Garcia A; Gillepsie S; Archibald HL; Gomez-Caraballo M; Nulton TJ; Windle BE; Piotrowska Z; Sahingur SE; Taylor SM; Dozmorov M; Sequist LV; Bernstein B; Ebi H; Engelman JA; Faber AC
Clin Cancer Res; 2018 Jan; 24(1):197-208. PubMed ID: 29051323
[No Abstract] [Full Text] [Related]
7. Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway.
Ravi J; Elbaz M; Wani NA; Nasser MW; Ganju RK
Mol Carcinog; 2016 Dec; 55(12):2063-2076. PubMed ID: 26741322
[TBL] [Abstract][Full Text] [Related]
8. Co-Expression Network Analysis Unveiled lncRNA-mRNA Links Correlated to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance and/or Intermediate Epithelial-to-Mesenchymal Transition Phenotypes in a Human Non-Small Cell Lung Cancer Cellular Model System.
Fustaino V; Papoff G; Ruberti F; Ruberti G
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612674
[TBL] [Abstract][Full Text] [Related]
9. Intervention of AXL in EGFR Signaling via Phosphorylation and Stabilization of MIG6 in Non-Small Cell Lung Cancer.
Yang YY; Lin SC; Lay JD; Cho CY; Jang TH; Ku HY; Yao CJ; Chuang SE
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834326
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of GPR30 sensitized gefitinib to NSCLC cells via regulation of epithelial-mesenchymal transition.
Yang X; Jiang H; Ning J; Zhang S; Cai Y; Wang L; Yang J; Xu G; Chen W; Wang J
Int J Immunopathol Pharmacol; 2023; 37():3946320231210737. PubMed ID: 37890097
[No Abstract] [Full Text] [Related]
11. Root Extract of
Park HJ; Park SH
Nutr Cancer; 2023; 75(10):1945-1957. PubMed ID: 37870977
[TBL] [Abstract][Full Text] [Related]
12. CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS Progression.
Jurica JM; Carsten B; Balakhani S; Haag MM; Aisner DL; Camidge DR
Clin Lung Cancer; 2024 Jan; 25(1):77-79. PubMed ID: 37932178
[No Abstract] [Full Text] [Related]
13. GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells.
Wan X; Fang Y; Du J; Cai S; Dong H
Onco Targets Ther; 2023; 16():913-922. PubMed ID: 38021444
[TBL] [Abstract][Full Text] [Related]
14. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.
Huang S; Hölzel M; Knijnenburg T; Schlicker A; Roepman P; McDermott U; Garnett M; Grernrum W; Sun C; Prahallad A; Groenendijk FH; Mittempergher L; Nijkamp W; Neefjes J; Salazar R; Ten Dijke P; Uramoto H; Tanaka F; Beijersbergen RL; Wessels LF; Bernards R
Cell; 2012 Nov; 151(5):937-50. PubMed ID: 23178117
[TBL] [Abstract][Full Text] [Related]
15. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
Malchers F; Nogova L; van Attekum MH; Maas L; Brägelmann J; Bartenhagen C; Girard L; Bosco G; Dahmen I; Michels S; Weeden CE; Scheel AH; Meder L; Golfmann K; Schuldt P; Siemanowski J; Rehker J; Merkelbach-Bruse S; Menon R; Gautschi O; Heuckmann JM; Brambilla E; Asselin-Labat ML; Persigehl T; Minna JD; Walczak H; Ullrich RT; Fischer M; Reinhardt HC; Wolf J; Büttner R; Peifer M; George J; Thomas RK
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37606995
[TBL] [Abstract][Full Text] [Related]
16. Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition.
Kapeleris J; Müller Bark J; Ranjit S; Richard D; Vela I; O'Byrne K; Punyadeera C
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3501-3510. PubMed ID: 35932303
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Insights into Yifei Sanjie Pill's Regulation of EMT to Enhance Gefitinib Treatment effect in NSCLC by in silico analysis and experimental validation.
Zhou R; Qin B; Zhuang Z; Li J; Tiangi Gao YS; Wu D; Yuan Y; Tang Y; Lin L
J Ethnopharmacol; 2024 May; ():118343. PubMed ID: 38750985
[TBL] [Abstract][Full Text] [Related]
18. Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
Mäkinen N; Meyerson M
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37909331
[TBL] [Abstract][Full Text] [Related]
19. FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes.
Furugaki K; Fujimura T; Mizuta H; Yoshimoto T; Asakawa T; Yoshimura Y; Yoshiura S
NPJ Precis Oncol; 2023 Oct; 7(1):107. PubMed ID: 37880373
[TBL] [Abstract][Full Text] [Related]
20. The D647N mutation of FGFR1 induces ligand-independent receptor activation.
Domenichini M; Ravelli C; Corsini M; Codenotti S; Moreschi E; Gogna A; Capoferri D; Zizioli D; Bresciani R; Grillo E; Mitola S
Biochim Biophys Acta Gen Subj; 2023 Dec; 1867(12):130470. PubMed ID: 37778450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
